# INFOGRAPHIC: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from YOSEMITE and RHINE)

**Authors:** Naomi Wijesingha, Kara Gibson, Jeffrey R. Willis, Sobha Sivaprasad

PMC · DOI: 10.1038/s41433-024-03249-0 · Eye · 2024-07-29

## Full-text entities

- **Diseases:** diabetic macular oedema (MESH:D008269)
- **Chemicals:** faricimab (MESH:C000723200)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11841523/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11841523/full.md

---
Source: https://tomesphere.com/paper/PMC11841523